Join to view full profile
1800 Orleans StreetBaltimore, MD 21287
Phone+1 410-955-5000
Fax+1 410-955-5001
Dr. Eshleman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Blood Banking/Transfusion Medicine, 1992 - 1993- University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 1989 - 1992
Temple University HospitalInternship, Internal Medicine, 1988 - 1989
Perelman School of Medicine at the University of PennsylvaniaClass of 1988
Certifications & Licensure
MD State Medical License 1997 - 2028
PA State Medical License 1992 - 2006
OH State Medical License 1993 - 1998
American Board of Pathology Clinical Pathology
Publications & Presentations
PubMed
- INCREASED PREVALENCE OF PANCREATIC CYSTS IN NONSECRETOR (FUT2 NULL) INDIVIDUALS UNDER PANCREATIC SURVEILLANCE.Yuto Hozaka, Masataka Hayashi, Emy Abou Sleiman, Bryson W Katona, Randall E Brand
Cancer Epidemiology, Biomarkers & Prevention. 2026-10-08 - Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations With Race and Prostate Cancer Outcomes.Karen S Sfanos, Rebecca Morton, Julia N Flores, Rebecca Y Sosa, Sarah E Ernst
Modern Pathology. 2026-10-01 - 4 citationsSimultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer.Selina Shiqing K Teh, Akhil Kotwal, Alexis Bennett, Eitan Halper-Stromberg, Laura Morsberger
The Journal of Clinical Investigation. 2026-05-15
Journal Articles
- Clinical Validation of Coexisting Driver Mutations in Colorectal CancersJunaid Ibrahim, James R Eshleman, Gang Zheng, Christopher D Gocke, Rena Xian, ScienceDirect
Press Mentions
FDA Clears Promega OncoMate™ MSI Dx Analysis SystemJuly 28th, 2021- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyFebruary 10th, 2016
Grant Support
- Identifying Familial Pancreatic Cancer Predisposition GenesNational Cancer Institute2012
- Novel Human Cancer Cell Isolation SystemNational Cancer Institute2008–2011
- Novel Tumor Suppressor Gene Discovery In Pancreatic CancerNational Cancer Institute2007–2008
- Mutator Phenotypes In Microsatellite Stable Colon CancerNational Cancer Institute1999–2003
- Mechanisms Underlying Genetic Defects In Colon CancerNational Cancer Institute1997–2000
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/james-eshleman
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: